醫思健康(02138.HK)中期純利增加267.8%至1.96億港元 中期息10.2港仙
格隆匯11月26日丨醫思健康(02138.HK)公佈,截至2021年9月30日止六個月,公司總收入增加81.1%至14.44億港元,淨溢利增加267.8%至1.96億港元,每股基本盈利為14.2港仙,董事會宣派中期股息每股股份10.2港仙,並將以現金支付。
期內銷售額由上年同期的9.47億港元增加61.8%至期間15.32億港元。新型冠狀病毒疫情後人們變得更加註重健康,因而對醫療保健服務的需求增加。醫療服務仍然是集團的主要增長動力。報吿期內,醫療服務貢獻的收入為7.58億港元,較去年同期增長109.9%,佔本集團收入的52.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.